VIRI Virios Therapeutics, Inc.

Virios Therapeutics, LLC, a development-stage biotechnology company, focuses on developing antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. Its lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia. The company was formerly known as Innovative Med Concepts, LLC and changed its name to Virios Therapeutics, LLC in July 2020. Virios Therapeutics, LLC was founded in 2012 and is headquartered in Alpharetta, Georgia.

$6.77
As of 06/24/2021     IEX book   CBOE book


Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  12/17/2020
Outstanding shares:  8,330,390
Average volume:  211,538
Market cap:   $54,147,535
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    92829J104
ISIN:        US92829J1043
Sedol:      BN767R7
Valuation   (See tab for details)
PE ratio:   0.00
PB ratio:   2.14
PS ratio:   0.00
Return on equity:   0.00%
Net income %:   0.00%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy